[
  {
    "ts": null,
    "headline": "Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight",
    "summary": "DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).",
    "url": "https://finnhub.io/api/news?id=65e1cc58120a749c89e814beaf1abc720f52cd5e3892217401762423017eac1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766010660,
      "headline": "Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight",
      "id": 137816777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).",
      "url": "https://finnhub.io/api/news?id=65e1cc58120a749c89e814beaf1abc720f52cd5e3892217401762423017eac1f"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Sees Mixed Analyst Views as Europe Advances WINREVAIR Review",
    "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Merck & Co., Inc. is among the most undervalued stocks. On December 12, 2025, Morgan Stanley analyst Terence Flynn reiterated an Equal Weight rating on MRK and raised the price target from $100 to $102 in a research note to […]",
    "url": "https://finnhub.io/api/news?id=af574f291f5f84cac0fe87ef5eb0ffb2af9814fdfdebacc27ff596a5de3042bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766009425,
      "headline": "Merck & Co., Inc. (MRK) Sees Mixed Analyst Views as Europe Advances WINREVAIR Review",
      "id": 137817040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Merck & Co., Inc. is among the most undervalued stocks. On December 12, 2025, Morgan Stanley analyst Terence Flynn reiterated an Equal Weight rating on MRK and raised the price target from $100 to $102 in a research note to […]",
      "url": "https://finnhub.io/api/news?id=af574f291f5f84cac0fe87ef5eb0ffb2af9814fdfdebacc27ff596a5de3042bd"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma stocks 'way undervalued,' says market expert",
    "summary": "STORY: Coons noted that although regulatory changes have \"weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly.\"The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.Lilly also produces Kisunla, a drug to slow Alzheimer's.\"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market,\" said Coons, who added, \"we do like Merck as well.\"",
    "url": "https://finnhub.io/api/news?id=55f9d1bbd3406c8711a4c1173db089e442da61358734ac32d5d8326f83dd4030",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766006759,
      "headline": "Big Pharma stocks 'way undervalued,' says market expert",
      "id": 137816778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "STORY: Coons noted that although regulatory changes have \"weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly.\"The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.Lilly also produces Kisunla, a drug to slow Alzheimer's.\"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market,\" said Coons, who added, \"we do like Merck as well.\"",
      "url": "https://finnhub.io/api/news?id=55f9d1bbd3406c8711a4c1173db089e442da61358734ac32d5d8326f83dd4030"
    }
  },
  {
    "ts": null,
    "headline": "BofA Turns More Positive on Merck (MRK) Pipeline",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Merck & Co., Inc. (NYSE:MRK) to $120 from $105 and kept a Buy rating. The analyst said the stock is starting to look more appealing as the pipeline […]",
    "url": "https://finnhub.io/api/news?id=1910ee29a64b1f829897c29d500f5ec6712dffc1b90b420a90c5066b3ff0ee48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765999211,
      "headline": "BofA Turns More Positive on Merck (MRK) Pipeline",
      "id": 137817043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Merck & Co., Inc. (NYSE:MRK) to $120 from $105 and kept a Buy rating. The analyst said the stock is starting to look more appealing as the pipeline […]",
      "url": "https://finnhub.io/api/news?id=1910ee29a64b1f829897c29d500f5ec6712dffc1b90b420a90c5066b3ff0ee48"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: This ETF Stinks",
    "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
    "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765997441,
      "headline": "SCHD: This ETF Stinks",
      "id": 137814928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364623580/image_1364623580.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
      "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK): Valuation Check After Promising KEYTRUDA Plus Padcev Phase 3 Bladder Cancer Results",
    "summary": "Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA plus Padcev improved survival outcomes for muscle invasive bladder cancer patients compared with standard chemotherapy and surgery. See our latest analysis for Merck. Despite the headline grabbing oncology wins and regulatory progress on drugs like Winrevair, Merck’s 90 day share price return of 21.11 percent has not yet translated into outsized long term total shareholder...",
    "url": "https://finnhub.io/api/news?id=f1620440d13f4e2d18eeb69c8121cbf5896f4a55f13db8e3b81caefce6347188",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765987897,
      "headline": "Merck (MRK): Valuation Check After Promising KEYTRUDA Plus Padcev Phase 3 Bladder Cancer Results",
      "id": 137817044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA plus Padcev improved survival outcomes for muscle invasive bladder cancer patients compared with standard chemotherapy and surgery. See our latest analysis for Merck. Despite the headline grabbing oncology wins and regulatory progress on drugs like Winrevair, Merck’s 90 day share price return of 21.11 percent has not yet translated into outsized long term total shareholder...",
      "url": "https://finnhub.io/api/news?id=f1620440d13f4e2d18eeb69c8121cbf5896f4a55f13db8e3b81caefce6347188"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug",
    "summary": "Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.",
    "url": "https://finnhub.io/api/news?id=cff384edce35c333e2da82a046a501b89eb5bb0687d038600a5b9cd79bd45539",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765978980,
      "headline": "FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug",
      "id": 137817045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.",
      "url": "https://finnhub.io/api/news?id=cff384edce35c333e2da82a046a501b89eb5bb0687d038600a5b9cd79bd45539"
    }
  },
  {
    "ts": null,
    "headline": "The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now",
    "summary": "It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.",
    "url": "https://finnhub.io/api/news?id=06f7a6a5736ea3dcfc0cfc65be9da91695de8240065b8d8cbd59ba0a004083c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765978500,
      "headline": "The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now",
      "id": 137816783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.",
      "url": "https://finnhub.io/api/news?id=06f7a6a5736ea3dcfc0cfc65be9da91695de8240065b8d8cbd59ba0a004083c8"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery",
    "summary": "RAHWAY, N.J., December 17, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signifi",
    "url": "https://finnhub.io/api/news?id=cded5614f788e827a2b3aba008fabd14021b03232ffb27e998122683e9ed6551",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765971900,
      "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery",
      "id": 137817047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 17, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signifi",
      "url": "https://finnhub.io/api/news?id=cded5614f788e827a2b3aba008fabd14021b03232ffb27e998122683e9ed6551"
    }
  }
]